earnings
confidence high
sentiment positive
materiality 0.75
Medtronic Q3 FY2025 revenue $8.3B, EPS $1.39 non-GAAP beat; organic growth 4.1%
Medtronic plc
2025-Q3 EPS
reported $2.79
vs consensus $1.24
▲ beat
(+124.7%)
- Revenue $8.292B (+2.5% reported, +4.1% organic); GAAP EPS $1.01 (+2%), non-GAAP EPS $1.39 (+7%, above guidance).
- Cardiovascular up 5% organic led by PFA (low-20s growth) and Micra (mid-20s growth); Diabetes up 10.4% organic.
- Neuroscience up 5.2% organic (Neuromodulation low-double digit); Medical Surgical down 0.4% organic.
- FY25 guidance reaffirmed: organic rev growth 4.75%-5%, non-GAAP EPS $5.44-$5.50.
- CMS opened NCA for Renal Denervation; FDA approved additional PFA manufacturing site in Galway.